In a filing, Adaptive Biotechnologies Corp revealed its Officer KYLE PISKEL acquired Company’s shares for reported $3.21 million on Nov 28 ’25. In the deal valued at $19.72 per share,162,820 shares were bought.
Then, Chad Robins bought 35,736 shares, generating $704,714 in total proceeds.
Before that, BENZENO SHARON sold 308,477 shares. Adaptive Biotechnologies Corp shares valued at $5,216,346 were divested by the Chief Commercial Ofc Imm Med at a price of $16.91 per share. As a result of the transaction, BENZENO SHARON now holds 296,791 shares, worth roughly $5.83 million.
Guggenheim initiated its Adaptive Biotechnologies Corp [ADPT] rating to a Buy in a research note published on September 30, 2025; the price target was $20. A number of analysts have revised their coverage, including Craig Hallum’s analysts, who began to cover the stock in mid June with a ‘”a Buy”‘ rating. Goldman also remained covering ADPT and has increased its forecast on March 21, 2025 with a “Buy” recommendation from previously “Neutral” rating.
Price Performance Review of ADPT
On Friday, Adaptive Biotechnologies Corp [NASDAQ:ADPT] saw its stock fall -0.30% to $19.66. Over the last five days, the stock has gained 20.47%. Adaptive Biotechnologies Corp shares have risen nearly 252.33% since the year began. Nevertheless, the stocks have risen 227.94% over the past one year. While a 52-week high of $20.76 was reached on 11/25/25, a 52-week low of $5.52 was recorded on 01/02/25.
Levels Of Support And Resistance For ADPT Stock
The 24-hour chart illustrates a support level at 19.37, which if violated will result in even more drops to 19.07. On the upside, there is a resistance level at 19.84. A further resistance level may holdings at 20.01.
How much short interest is there in Adaptive Biotechnologies Corp?
A steep rise in short interest was recorded in Adaptive Biotechnologies Corp stocks on 2025-11-14, growing by 1.34 million shares to a total of 10.37 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 9.03 million shares. There was a rise of 12.94%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 05, 2023 when Scotiabank began covering the stock and recommended ‘”a Sector outperform”‘ rating along with a $15 price target.
